콘텐츠로 건너뛰기
Merck
모든 사진(1)

주요 문서

모든 문서 보기

P8828

Sigma-Aldrich

Pergolide mesylate salt

≥98%, solid

동의어(들):

8β-[(Methylthio)methyl]-6-propylergoline methanesulfonate salt, Pergolide methanesulfonate salt

로그인조직 및 계약 가격 보기
모든 사진(1)

About This Item

실험식(Hill 표기법):
C19H26N2S · CH4O3S
CAS Number:
66104-23-2
Molecular Weight:
410.59
MDL number:
MFCD00153859
UNSPSC 코드:
12352200
PubChem Substance ID:
24277927
NACRES:
NA.77

분석

≥98%

양식

solid

광학 활성

[α]20/D −35°, c = 0.2 in pyridine(lit.)

색상

white

solubility

ethanol: 2 mg/mL
DMSO: 5.2 mg/mL
H2O: insoluble

주관자

Valeant

저장 온도

−20°C

SMILES string

CS(O)(=O)=O.[H][C@@]12Cc3c[nH]c4cccc(c34)[C@@]1([H])C[C@@H](CSC)CN2CCC

InChI

1S/C19H26N2S.CH4O3S/c1-3-7-21-11-13(12-22-2)8-16-15-5-4-6-17-19(15)14(10-20-17)9-18(16)21;1-5(2,3)4/h4-6,10,13,16,18,20H,3,7-9,11-12H2,1-2H3;1H3,(H,2,3,4)/t13-,16-,18-;/m1./s1

InChI key

UWCVGPLTGZWHGS-ZORIOUSZSA-N

유전자 정보

human ... DRD1(1812) , DRD2(1813) , DRD3(1814) , DRD4(1815) , DRD5(1816)

유사한 제품을 찾으십니까? 방문 제품 비교 안내

생화학적/생리학적 작용

Dopaminergic agonist; suppresses pituitary secretion of prolactin; anti-Parkinsonian agent.

특징 및 장점

This compound was developed by Valeant. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

픽토그램

Skull and crossbones
GHS06

신호어

Danger

유해 및 위험 성명서

H300

예방조치 성명서

P264 - P301 + P310

Hazard Classifications

Acute Tox. 2 Oral

Storage Class Code

6.1B - Non-combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

WGK

WGK 3

Flash Point (°F)

Not applicable

Flash Point (°C)

Not applicable

개인 보호 장비

Eyeshields, Faceshields, Gloves, type P3 (EN 143) respirator cartridges

가장 최신 버전 중 하나를 선택하세요:

시험 성적서(COA)

Lot/Batch Number
SLBM6092V
SLBF6838V
070M2011V
070M2011
119K1638

적합한 버전을 찾을 수 없으신가요?

특정 버전이 필요한 경우 로트 번호나 배치 번호로 특정 인증서를 찾을 수 있습니다.

COA 검색

이 제품을 이미 가지고 계십니까?

문서 라이브러리에서 최근에 구매한 제품에 대한 문서를 찾아보세요.

문서 라이브러리 방문

P Barone et al.
Neurology, 53(3), 573-579 (1999-08-17)
To determine whether pergolide monotherapy provides symptomatic relief in early PD. Early treatment with dopamine agonists may reduce the risk of motor fluctuations, which are most likely linked to levodopa therapy. Pergolide, a D1-D2 dopamine agonist, has been studied as
Hanna Scholz et al.
The Cochrane database of systematic reviews, (3)(3), CD006009-CD006009 (2011-03-18)
According to clinical guidelines, dopamine agonists are the first-line treatment of restless legs syndrome (RLS). To evaluate efficacy and safety of dopamine agonists for RLS. We searched the Cochrane Central Register of Controlled Trials (The Cochrane Library 2008, Issue 4)
Richard P Allen et al.
Sleep medicine, 12(5), 431-439 (2011-04-16)
Assess the rate of augmentation as it occurs during standard long-term dopaminergic treatment of RLS, potential risk factors or predictors of augmentation, the relationship between treatment duration and augmentation, and the clinical impact of augmentation on subjects' health outcomes. Two
Marie Innerå et al.
Veterinary dermatology, 24(1), 212-217 (2013-01-22)
Pituitary pars intermedia dysfunction (PPID) in older equids is commonly recognized by a long hair coat that fails to shed. The aim of this study was to compare hair follicle stages in PPID-affected horses with excessively long hair coats with
Alin Ciobica et al.
Journal of physiology and biochemistry, 68(1), 59-69 (2011-10-19)
One of the most widely used animal models of Parkinson's disease (PD) involves injecting 6-hydroxydopamine (6-OHDA) directly into the substantia nigra (SN). Some recent reports speculated that dopaminergic drugs may exert brain antioxidant activity, which could explain some of their
모든 관련된 서류 보기

자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..

고객지원팀으로 연락바랍니다.